Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.
Applied DNA Sciences, Inc. (APDN) delivers innovative synthetic DNA solutions for therapeutic development, molecular diagnostics, and supply chain security. This news hub provides investors and industry professionals with centralized access to official corporate announcements and verified updates.
Track critical developments across the company's core operations, including advancements in PCR-based DNA production, diagnostic testing services, and anti-counterfeiting technologies. Our curated feed features earnings reports, strategic partnerships, product launches, and regulatory milestones that impact APDN's market position.
Key focus areas include updates on the Linea DNA platform for mRNA therapeutics, CertainT forensic authentication solutions, and clinical testing services. Users benefit from timestamped press releases organized chronologically while maintaining factual accuracy and regulatory compliance.
Bookmark this page for direct access to Applied DNA Sciences' latest financial disclosures, technology patents, and supply chain security initiatives. Check regularly for updates on nucleic acid manufacturing innovations and DNA-based brand protection programs shaping the biotechnology sector.
Applied DNA Sciences (NASDAQ: APDN) has announced its COVID-19 diagnostic strategy to address the Omicron variant. The Linea 2.0 COVID-19 Assay is set for submission to the New York Department of Health, improving upon the existing Linea 1.0 Assay. The Linea 1.0 Assay shows a unique double S-gene target failure, which may lead to false negatives for Omicron but allows reliable reflex testing. Validation data for Linea 2.0 indicate enhanced performance. The company remains committed to high-quality PCR testing amid the evolving virus landscape.
Applied DNA Sciences (NASDAQ: APDN) reported a surge in demand for its LinearDNA™ from diagnostic customers and a new order from a Contract Research Organization (CRO) specializing in cancer research. The company has noted an increase in CRO orders, indicating growing adoption for therapeutic DNA in cell and gene therapies. CEO Dr. James A. Hayward highlighted the potential for LinearDNA to disrupt existing plasmid DNA manufacturing methods, particularly amid the rising need for scalable, high-quality DNA in therapeutic applications. This shift positions Applied DNA favorably in the growing gene therapy market.
Applied DNA Sciences, Inc. (NASDAQ: APDN) announced a new study published in Molecular Therapy: Methods and Clinical Development demonstrating the use of its proprietary LinearDNA™ technology for manufacturing CAR19 T-cells. This research indicates that CAR T-cells produced using LinearDNA show equivalent efficacy to those made with traditional plasmid DNA, presenting a more cost-effective and efficient production method. The study highlights LinearDNA's advantages, including >99% purity without the need for typical purification processes, potentially accelerating CAR T-cell therapy development.
Applied DNA Sciences (NASDAQ: APDN) and CLEARED4 have launched an integrated platform to assist large employers in complying with OSHA's Emergency Temporary Standard (ETS) regarding COVID-19 vaccination and testing. This comprehensive solution offers vaccine status management and weekly pooled COVID-19 testing via Applied DNA's safeCircle platform. Employers must ensure compliance by January 4, 2022, for workforces of 100 or more. The platform is already in use by various educational institutes and businesses to streamline health verification and testing processes.
Applied DNA Sciences (NASDAQ: APDN) has submitted a request for Emergency Use Authorization (EUA) from the FDA for its Linea™ SARS-CoV-2 Mutation Panel, which detects four SARS-CoV-2 mutations. Three of these mutations (E484K, L452R, N501Y) are classified by the CDC as substitutions of therapeutic concern, potentially impacting monoclonal antibody treatment efficacy. The panel aims to serve as a rapid alternative to Next Generation Sequencing for identifying COVID-19 patients with these mutations, which have shown 100% concordance with NGS results.
Applied DNA Sciences (NASDAQ: APDN) announced a collaboration with Ganesha Ecosphere Ltd., India's largest recycled polyester fiber producer. The agreement allows Ganesha to use Applied DNA's CertainT® platform for traceability in its recycled polyester production. This partnership aims to enhance sustainability in the textile industry by verifying raw materials through Applied DNA’s proprietary SigNature® T-100 tracer system. Ganesha, established in 1994, has a production capacity of 118,800 metric tons per year and serves over 300 customers.
Applied DNA Sciences (NASDAQ: APDN) has launched its COVID-19 testing program, safeCircle™, at Sarah Lawrence College to monitor virus prevalence among its population of 2,000 individuals. This program complements the College’s vaccine mandate and features on-site sample collection with quick turnaround times for test results. Mike Munzer from Applied DNA emphasized the importance of testing in light of the Delta variant's transmissibility. The safeCircle program utilizes high-sensitivity pooled RT-PCR testing, aiming to enhance safety on campus.
Applied DNA Sciences (NASDAQ: APDN) announced $1.6 million in purchase orders from a textile customer for molecular taggant to tag textile fibers. Most shipments are expected by September 30, 2021. The company is also progressing textile projects with major apparel brands, which could open new commercial opportunities in fiscal 2022. The CertainT® traceability platform supports supply chain transparency from fiber to finished goods, increasingly in demand post-pandemic.
Applied DNA Sciences, Inc. (NASDAQ: APDN) has enhanced its partnership with TruTrace Technologies to support the StrainSecure 2.0 platform, aimed at improving cannabis product validation and supply chain transparency. This integration follows their strategic alliance launched in January 2021. StrainSecure 2.0 will help cannabis companies meet growing regulations and provide enhanced product authenticity. Key features include a shared ledger for tracking cannabis products and a marketing tool for real-time product data. This collaboration seeks to mitigate risks and ensure compliance in the evolving cannabis industry.
Applied DNA Sciences (NASDAQ: APDN) has signed a Master Services Agreement with Flora Growth (NASDAQ: FLGC) to integrate its CertainT® platform for cannabis product validation and authentication. The company will implement this technology across three locations (1 in Florida, 2 in Colombia) to enhance supply chain transparency and product trust. The CertainT platform, which includes molecular tagging, aims to support Flora's global distribution strategy and compliance with pharmaceutical standards as they expand in international markets like Australia. Financial details were not disclosed.
